Comparative Pharmacology
Head-to-head clinical analysis: ULTRAGRIS 165 versus ULTRAGRIS 330.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULTRAGRIS 165 versus ULTRAGRIS 330.
ULTRAGRIS-165 vs ULTRAGRIS-330
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ULTRAGRIS-165 is a combination of the antifungal agent griseofulvin and a synthetic corticosteroid, which inhibits fungal cell mitosis by binding to tubulin and disrupting microtubule function, while the corticosteroid reduces inflammation via glucocorticoid receptor activation.
Ultrasound contrast agent; microbubbles of perflutren enhance echogenicity and improve visualization of cardiac structures and blood flow.
160 mg orally every 6 hours or 300 mg orally every 12 hours; total daily dose not to exceed 1500 mg.
330 mg orally once daily
None Documented
None Documented
Terminal elimination half-life of 8–10 hours in healthy adults; prolonged to 15–20 hours in severe renal impairment (CrCl <30 mL/min).
12 hours (renal impairment prolongs to 24 hours)
Primarily renal (70-80% unchanged), with 15-20% biliary/fecal. Total clearance 120 mL/min.
Renal (60% unchanged; 30% as glucuronide conjugate), biliary (10%)
Category C
Category C
Antifungal (Griseofulvin)
Antifungal (Griseofulvin)